Last reviewed · How we verify

NCT03063554: BILPAL

EUS BD vs ERCP TP for Pancreatic Cancer

Status unknown NA Last updated 24 February 2017
What this trial tests

NA trial testing Endoscopic Ultrasound Guided Biliary Drainage in Pancreatic Cancer in 120 participants. Status unknown.

Timeline
18 October 2016
Primary endpoint
1 September 2018
1 October 2018

Quick facts

Lead sponsorWeill Medical College of Cornell University
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment120
Start date18 October 2016
Primary completion1 September 2018
Estimated completion1 October 2018
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Weill Medical College of Cornell University

Who can join

Adults 18 to 90, any sex, with Pancreatic Cancer or Pancreatic Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This Endoscopic Ultrasound guided Biliary Drainage (EUS-BD) vs. Endoscopic Retrograde Cholangiopancreatography (ERCP-TP) trial (BILPAL) is a randomized controlled multicenter trial that will provide evidence whether or not traditional ERCP biliary drainage is to be performed in patients with obstruction in bile duct due to unresectable pancreatic head or periampullary tumor.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Pancreatic Cancer

Currently open trials in the same condition.

Other Weill Medical College of Cornell University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03063554.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing